RNA as a target for small molecules.

Proteins are folded to form a small binding site for catalysis or ligand recognition and this small binding site is traditionally the target for drug discovery. An alternative target for potential drug candidates is the translational process, which requires a precise reading of the entire mRNA sequence and, therefore, can be interrupted with small molecules that bind to mRNA sequence-specifically. RNA thus presents itself as a new upstream target for drug discovery because of the critical role it plays in the life of pathogens and in the progression of diseases. In this post-genomic era, RNA is becoming increasingly amenable to small-molecule therapy as greater structural and functional information accumulates with regard to important RNA functional domains. The study of aminoglycoside antibiotics and their binding to 16S ribosomal RNA has been a paradigm for our understanding of the ways in which small molecules can be developed to affect the function of RNA.

[1]  M Afshar,et al.  Structure-based and combinatorial search for new RNA-binding drugs. , 1999, Current opinion in biotechnology.

[2]  A. W. Czarnik,et al.  Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules. , 1998, Biochemistry.

[3]  R. Griffey,et al.  Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Green,et al.  Importance of Ribosomal Frameshifting for Human Immunodeficiency Virus Type 1 Particle Assembly and Replication , 1998, Journal of Virology.

[5]  J. Karn,et al.  High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. , 1993, Journal of molecular biology.

[6]  O. Uhlenbeck,et al.  Inhibition of the hammerhead ribozyme by neomycin. , 1969, RNA.

[7]  J. Modolell,et al.  Functional interaction of neomycin B and related antibiotics with 30S and 50S ribosomal subunits. , 1979, Biochemical and biophysical research communications.

[8]  Chi‐Huey Wong,et al.  Rapid Combinatorial Synthesis of Aminoglycoside Antibiotic Mimetics: Use of a Polyethylene Glycol-Linked Amine and a Neamine-Derived Aldehyde in Multiple Component Condensation as a Strategy for the Discovery of New Inhibitors of the HIV RNA Rev Responsive Element , 1996 .

[9]  M. Ehrenberg,et al.  Ribosomal RNA and protein mutants resistant to spectinomycin. , 1990, The EMBO journal.

[10]  G. F. Joyce,et al.  Direct observation of aminoglycoside-RNA interactions by surface plasmon resonance. , 1997, Journal of the American Chemical Society.

[11]  W. Wilson,et al.  Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives. , 1996, Biochemistry.

[12]  J. Puglisi,et al.  Structural origins of gentamicin antibiotic action , 1998, The EMBO journal.

[13]  H. Noller,et al.  Footprinting the sites of interaction of antibiotics with catalytic group I intron RNA. , 1993, Science.

[14]  D. P. Mack,et al.  INHIBITION OF AN HIV-1 TAT-DERIVED PEPTIDE BINDING TO TAR RNA BY AMINOGLYCOSIDE ANTIBIOTICS , 1995 .

[15]  G. Varani,et al.  Recent solution structures of RNA and its complexes with drugs, peptides and proteins. , 1997, Current opinion in structural biology.

[16]  J. Williamson,et al.  Structure of the S15,S6,S18-rRNA complex: assembly of the 30S ribosome central domain. , 2000, Science.

[17]  S. P. Fodor,et al.  High density synthetic oligonucleotide arrays , 1999, Nature Genetics.

[18]  J. Chia,et al.  Inhibition of Hepatitis Delta Virus Genomic Ribozyme Self-Cleavage by Aminoglycosides. , 1997, Journal of biomedical science.

[19]  I. Weissman,et al.  Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus , 1988, Cell.

[20]  J. Karn,et al.  RNA recognition by the human immunodeficiency virus Tat and Rev proteins. , 1993, Trends in biochemical sciences.

[21]  W. Wilson,et al.  Design and analysis of molecular motifs for specific recognition of RNA. , 1997, Bioorganic & medicinal chemistry.

[22]  D. Steinhauer,et al.  Role of hemagglutinin cleavage for the pathogenicity of influenza virus. , 1999, Virology.

[23]  R. Griffey,et al.  Multiplexed screening of neutral mass-tagged RNA targets against ligand libraries with electrospray ionization FTICR MS: a paradigm for high-throughput affinity screening. , 1999, Analytical chemistry.

[24]  J. Puglisi,et al.  Structure of the A Site of Escherichia coli 16S Ribosomal RNA Complexed with an Aminoglycoside Antibiotic , 1996, Science.

[25]  Chi-Huey Wong,et al.  Design of Bifunctional Antibiotics that Target Bacterial rRNA and Inhibit Resistance-Causing Enzymes , 2000 .

[26]  R. Rando,et al.  Specific binding of aminoglycoside antibiotics to RNA. , 1995, Chemistry & biology.

[27]  A. Frankel,et al.  Selection of RNA-binding peptides in vivo , 1996, Nature.

[28]  Y Wang,et al.  Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region. , 1997, Biochemistry.

[29]  Y. Tor.  RNA and the Small Molecule World. , 1999, Angewandte Chemie.

[30]  E. Canaani,et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.

[31]  Hermann.  Strategies for the Design of Drugs Targeting RNA and RNA-Protein Complexes. , 2000, Angewandte Chemie.

[32]  R. Garrett,et al.  Puromycin-rRNA interaction sites at the peptidyl transferase center. , 2000, RNA.

[33]  M. Brink,et al.  Spectinomycin interacts specifically with the residues G1064 and C1192 in 16S rRNA, thereby potentially freezing this molecule into an inactive conformation. , 1994, Nucleic acids research.

[34]  J. Modolell,et al.  Dual interference of hygromycin B with ribosomal translocation and with aminoacyl-tRNA recognition. , 1978, European journal of biochemistry.

[35]  K Hamasaki,et al.  A high-throughput fluorescence screen to monitor the specific binding of antagonists to RNA targets. , 1998, Analytical biochemistry.

[36]  Sarah R. Kirk,et al.  Neomycin−Acridine Conjugate: A Potent Inhibitor of Rev-RRE Binding , 2000 .

[37]  J. Puglisi,et al.  Paromomycin binding induces a local conformational change in the A-site of 16 S rRNA. , 1998, Journal of molecular biology.

[38]  D. Bedwell,et al.  Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations , 1996, Nature Medicine.

[39]  D. Shinabarger.  Mechanism of action of the oxazolidinone antibacterial agents. , 1999, Expert opinion on investigational drugs.

[40]  A. W. Czarnik,et al.  Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism. , 1998, Biochemistry.

[41]  C. Sawyers,et al.  Signal transduction by wild-type and leukemogenic Abl proteins. , 1997, Biochimica et biophysica acta.

[42]  S. Mobashery,et al.  An Antibiotic Cloaked by Its Own Resistance Enzyme , 1999 .

[43]  Poul Nissen,et al.  Placement of protein and RNA structures into a 5 Å-resolution map of the 50S ribosomal subunit , 1999, Nature.

[44]  Michael R. Green,et al.  Small molecules that selectively block RNA binding of HIV-1 rev protein inhibit rev function and viral production , 1993, Cell.

[45]  Harry F. Noller,et al.  Interaction of antibiotics with functional sites in 16S ribosomal RNA , 1987, Nature.

[46]  H. Noller,et al.  Interaction of antibiotics with A‐ and P‐site‐specific bases in 16S ribosomal RNA. , 1991, The EMBO journal.

[47]  C. Bailly,et al.  Molecular basis of HIV-1 TAR RNA specific recognition by an acridine tat-antagonist. , 1999, Bioorganic & medicinal chemistry.

[48]  J. Steitz,et al.  The 3' terminus of 16S rRNA: secondary structure and interaction with ribosomal protein S1. , 1979, Nucleic acids research.

[49]  M. Green,et al.  Controlling gene expression in living cells through small molecule-RNA interactions. , 1998, Science.

[50]  D. Patel,et al.  Saccharide-RNA recognition in an aminoglycoside antibiotic-RNA aptamer complex. , 1997, Chemistry & biology.

[51]  Chi‐Huey Wong,et al.  Design of Small Molecules That Recognize RNA: Development of Aminoglycosides as Potential Antitumor Agents That Target Oncogenic RNA Sequences , 2000 .

[52]  Y. Tor,et al.  Designing Novel RNA Binders , 1998 .

[53]  D. Draper,et al.  Interaction of thiostrepton with an RNA fragment derived from the plastid-encoded ribosomal RNA of the malaria parasite. , 1997, RNA.

[54]  Chi‐Huey Wong,et al.  Hydroxyamines as a New Motif for the Molecular Recognition of Phosphodiesters: Implications for Aminogloycoside–RNA Interactions , 1997 .

[55]  I D Kuntz,et al.  Structure-based discovery of ligands targeted to the RNA double helix. , 1997, Biochemistry.

[56]  S. Yokoyama,et al.  An antibiotic-binding motif of an RNA fragment derived from the A-site-related region of Escherichia coli 16S rRNA. , 1996, Nucleic acids research.

[57]  R. Garrett,et al.  Binding sites of the antibiotics pactamycin and celesticetin on ribosomal RNAs. , 1991, Biochimie.

[58]  T. Klimkait,et al.  A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. , 1998, Biochemistry.

[59]  J. Puglisi,et al.  RNA sequence determinants for aminoglycoside binding to an A-site rRNA model oligonucleotide. , 1996, Journal of molecular biology.

[60]  Batey,et al.  Tertiary Motifs in RNA Structure and Folding. , 1999, Angewandte Chemie.

[61]  Volchkov Ve.  Processing of the Ebola virus glycoprotein , 1999 .

[62]  G. Steiner,et al.  Interaction of tetracycline with RNA: photoincorporation into ribosomal RNA of Escherichia coli. , 1997, Nucleic acids research.

[63]  N. Tanaka,et al.  Interaction of kanamycin and related antibiotics with the large subunit of ribosomes and the inhibition of translocation. , 1978, Biochemical and biophysical research communications.

[64]  E Westhof,et al.  RNA as a drug target: chemical, modelling, and evolutionary tools. , 1998, Current opinion in biotechnology.